Biotech Investor-Readiness Advisory
Turn Strong Science Into an Investment Case
For biotech founders, academic spinouts, and researchers preparing to commercialize a discovery.
You have the science. But can you make the investment case?
Early-stage biotech companies often have compelling scientific data but struggle to translate that science into the market, clinical, competitive, and financial story investors need to evaluate an opportunity.
KG-STEM Advisory Group helps bridge that gap.
We combine biotechnology and life-sciences experience with financial modeling, valuation, and business strategy to help founders turn complex scientific work into a clear, defensible, investor-ready case.
From Scientific Potential to Investor Readiness
Investors need to understand more than whether the science works. They need to understand why it matters, how big the opportunity could be, what happens next, and how value can be created as risk is reduced.
We help you build that story.
01 | Scientific & Clinical Story
We examine how your scientific story will resonate with a non-scientific investor.
We help clarify the unmet need, scientific rationale, mechanism, differentiation, and evidence supporting the opportunity.
02 | Market & Competitive Landscape
We put the science into commercial context.
Our analysis can include competitors, comparable companies, relevant indications and mechanisms, clinical-stage positioning, and high-level market sizing.
03 | Clinical & Regulatory Pathway
We help translate your development strategy into an investor-legible roadmap.
We examine the current stage of development, anticipated clinical and regulatory milestones, potential value inflection points, and the path from the current program to the next major milestone.
04 | Financial & Valuation Narrative
Scientific milestones can change the value of a biotech company.
We help connect your development milestones to a financial and valuation framework, creating a narrative around how the opportunity could evolve as scientific and clinical risk is reduced.
05 | Investor Materials & Diligence Preparation
A strong story needs to be communicated consistently.
We help structure investor-facing materials and organize the supporting information investors may need to evaluate the opportunity, including the pitch narrative, executive summary, and data-room framework.
06 | Mock Investor Q&A
The hardest questions rarely arrive on the slide you prepared for.
We conduct structured mock investor and diligence sessions designed to pressure-test the scientific, commercial, clinical, financial, and strategic assumptions behind your story.
Who We Work With
KG-STEM works with:
Pre-seed through Series A biotech startups
Academic spinouts
Researchers commercializing discoveries
Early-stage life-sciences companies preparing for fundraising or a major value-inflection milestone
Our work is particularly relevant when a company has strong scientific foundations but needs a clearer connection between the science, the market opportunity, the development pathway, and potential value creation.
Why KG-STEM?
Biotech sits at the intersection of science and capital.
Many advisors bring financial expertise without meaningful scientific depth. Others understand the science but lack the financial and valuation framework investors use to assess opportunities.
KG-STEM was built to bridge those worlds.
Our founder brings more than a decade of biotechnology and life-sciences experience, an M.S. in Biotechnology from Johns Hopkins University, and specialized valuation and due diligence expertise.
The result is an advisory approach designed specifically for the realities of early-stage biotech.
Investor Readiness Without the Fundraising Conflicts
KG-STEM is an advisory firm, not a placement agent or fundraising intermediary.
We do not source or place capital, negotiate financing terms, or take a percentage of the capital you raise.
Our role is to help you become more prepared, more credible, and more effective when you engage investors.
You retain ownership of your science, intellectual property, data, and decisions. Our work is advisory and does not constitute legal, regulatory, tax, or investment advice.
Let’s See If We’re a Fit
Every biotech company is at a different stage. The right level of support depends on your science, development stage, fundraising objectives, and the questions you need to answer before approaching investors.
Start with a free 30-minute consultation.
We’ll discuss where your company is today, what you’re preparing for, and where you may need additional investor-readiness support.
No obligation. No pitch. Just a focused conversation about where you are and what comes next.
